HDL heterogeneity and atherosclerosis

Critical Reviews in Clinical Laboratory Sciences

Volumn 33, Issue 3, 1996, Pages 163-201

  Tailleux, A ^a   Fruchart, J C ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoprotein; Coronary heart disease; HDL cholesterol; Lipoprotein; Reverse cholesterol transport

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PRIMROSE OIL;

ADULT; AGED; ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; CHOLESTEROL ESTERIFICATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPOPROTEINEMIA; ELECTROIMMUNOASSAY; ELECTROPHORESIS; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; FEMALE; GENETIC HETEROGENEITY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; ISCHEMIC HEART DISEASE; ISOELECTRIC FOCUSING; LIPOPROTEIN METABOLISM; LONGEVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; ULTRACENTRIFUGATION;

PRIMULA;

EID: 0030057248     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408369609083060     Document Type: Review

References (168)

1. Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins, cardiovascular disease, and death. Framingham Study. Arch Intern Med 1980; 141: 1128-1131.
2. Assmann G, Schulte H. PROCAM-trial Hedingen. Zürich: Panscienta Verlag, 1986.
3. Frick HM. Helsinki Heart Study. Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245.
4. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-1058.
5. Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 1986; 78: 1410-1418.
6. Segrest JP, Jackson RL, Morisset JD, et al. A molecular theory of lipid-protien interaction in the lipoproteins. FEBS lett 1974; 38: 247-253.
7. Brewer HB Jr, Lux SE, Ronan R, et al. The primary structure of apolipoprotein from human high density lipoprotein family: apolipoprotein A-II. J Biol Chem 1972; 257: 7189-7195.
8. Mao STJ, Sparrow JT, Gilliam EB, et al. Mechanism of lipid-protein interaction in the plasma lipoproteins: lipid binding properties of a synthetic fragment of apolipoprotein AII. Biochemistry 1977; 16: 4150-4156.
9. Innerarity TL, Mahley RW, Weisgraber KH, et al. Apoprotein (E-AII) complex of human plasma lipoproteins. II. Receptor binding activity of high density lipoprotein subfraction modulated by the apolipoprotein (E-AII) complex. J Biol Chem 1978; 253: 6289-6295.
10. Weisgraber KH, Mahley RW. Apoprotein (E-AII) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in high density lipoprotein subfraction. J Biol Chem 1978; 98: 17-24.
11. Green PHR, Glickman RM, Riley JW, et al. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest 1980; 65: 911-919.
12. Weinberg RB, Dantzker C Patton CS. Sensitivity of serum apolipoprotein A-IV levels to changes in dietary fat content. Gastroenterology 1990; 253: 6281-6288.
13. Stein O, Stein Y, Lefevre M, et al. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta 1986; 878: 7-13.
14. Steinmetz A, Uterman G. Activation of lecithin : cholesterol acyl transferase by human apolipoprotein A-IV. J Biol Chem 1985; 260: 2258-2264.
15. Fujimoto K, Cardelli JA Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol 1992; 262: 1002-1006.
16. Rall SC, Weigraber KH Mahley RW. Human apo E. The complete amino acid sequence. J Biol Chem 1982; 257: 4171-4178.
17. Beisiegel U, Weber W, Ihrke G, et al. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341: 162-164.
18. Soutar AK, Garner GE, Baker GN, et al. Effect of the human plasma lipoproteins and phosphatidylcholine acyl donor on the activity of lecithin cholesteryl acyl transferase. Biochemistry 1975; 14: 3057-3064.
19. Bentgsson G, Olivecrona T. Lipoprotein lipase: some effect of activator proteins. Eur J Biochem 1980; 106: 549-555.
20. McCall MR, Nichols AV, Blanche PJ, et al. Lecithin : cholesterol acyltransferase induced transformation of HepG2 lipoproteins. J Lipid Res 1989; 30: 1579-1589.
21. Simard G, Loiseau D, Girault A, et al. Reactivity of HDL subfractions towards lecithin-cholesterol acyltransferase. Modulation by their content in free cholesterol. Biochim Biophys Acta 1989; 1005: 245-252.
22. Karpe F, Johansson J Carlson LA. Studies on the lecithin-cholesterol acyltransferase substrate properties of HDL as determined by its subclass distribution analysed by gradient gel electrophoresis. Biochim Biophys Acta 1990; 1042: 310-314.
23. Fielding CJ, Shore VG Fielding PE. Apolipoprotein cofactor of lecithin: cholesterol acyl transferase. Biochem Biophys Res Commun 1972; 46: 1493-1498.
24. Albers JJ, Tollefson JH, Chen CH, et al. Isolation and characterization of human plasma lipid transfer proteins. Arteriosclerosis 1984; 4: 49-58.
25. r 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J Biol Chem 1988; 263: 5020-5023.
26. De Lalla OF, Elliott HA Gofman JW. Ultracentrifugal studies of high density serum lipoproteins in clinically healthly adults. Am J Physiol 1954; 179: 333-337.
27. Blanche PJ, Gong EL, Forte TM, et al. Characterization of human high density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-419.
28. Gidez LI, Miller GJ, Burstein M, et al. Separation and quantification of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982; 23: 1206-1223.
29. Nestruck AC, Niedmann PD, Wieland H, et al. Chromatofocusing of human high density lipoproteins and isolation of lipoproteins A and AI. Biochim Biophys Acta 1983; 753: 65-73.
30. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing AI and AII particles and particles containing AI but no AII. J Biol Chem 1984; 259: 12201-12209.
31. Nowicka G, Brüning T, Böttcher A, et al. The macrophage interaction of HDL subclasses separated by free flow isotachophoresis. J Lipid Res 1990; 31: 1947-1963.
32. Schaefer EJ, Foster DM, Jenkins LL, et al. The composition and metabolism of high density lipoprotein subfractions. Lipids 1979; 14: 511-522.
33. Anderson DW, Nichols AV, Pan SS, et al. High density lipoprotein distribution: resolution and determination of three major components in a normal population. Atherosclerosis 1977; 29: 161-179.
34. Kostner GM, Patsch JR, Sailer S, et al. Polypeptide distribution of the main lipoprotein density classes separated from human plasma by rate zonal ultracentrifugation. Eur J Biochem 1974; 45: 611-621.
35. Weisgraber KH, Mahley RW. Subfractionation of human high density lipoprotein by heparin-sepharose affinity chromatography. J Lipid Res 1980; 21: 316-325.
36. 2). Clin Chim Acta 1973; 43: 223-226.
37. Alaupovic P. The physichochemical and immunological heterogeneity of human plasma high density lipoproteins. In: Miller NE and Miller GJ, eds. Clinical and metabolic aspects of high density lipoproteins. Pp 1-43. Amsterdam: Elsevier, 1985.
38. Nichols AV, Krauss RM Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol 1986; 128: 417-431.
39. Verdery RB, Benham JF, Baldwin HL, et al. Measurement of normative HDL subfraction cholesterol levels by Gaussian summation analysis of gradient gels. J Lipid Res 1989; 30: 1085-1095.
40. McVicar JP, Kunitake ST, Hamilton RL, et al. Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. Proc Natl Acad Sci USA 1984; 81: 1356-1360.
41. Barbaras R, Grimaldi P, Negrel R, et al. Characterization of high density lipoprotein binding and cholesterol efflux in cultured mouse adipose cells. Biochem Biophys Acta 1986; 888: 143-156.
42. Barbaras R, Puchois P, Fruchart JC, et al. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not LpAI:AII particles. Biochem Biophys Res Commun 1987; 142: 63-69.
43. Atmeh RF, Shepard J Packard CJ. Subpopulations of apolipoprotein AI in human high density lipoproteins: their metabolic properties and response to drug therapy. Biochim Biophys Acta 1983; 751: 175-188.
44. Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein AI-containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40.
45. Ohta T, Hattori S, Nishiyama S, et al. Studies on the lipid and apolipoprotein compositions of two species of apo AI-containing lipoproteins in normolipidemic males and females. J Lipid Res 1988; 29: 721-728.
46. Alaupovic P, Bekaert ED Koren E. In: Biotechnology of dyslipoproteinemia: atherosclerosis. Lenfant C, Albertini A, Paoletti R, Catapano AL, eds. P. 179. New York: Raven Press, 1990.
47. Kilsdonk EP, Van Gent T Van Tol A. Characterization of human high density lipoprotein subclasses LpAI and LpAI:AII and binding HepG2 cells. Biochim Biophys Acta 1990; 104: 205-212.
48. Cheung MC, Wolf AC, Lum KD, et al. Distribution and localization of lecithin-cholesterol acyltransferase and cholesteryl ester transfer activity in AI containing lipoproteins. J Lipid Res 1986; 27: 1135-1144.
49. Cheung MC, Wolf AC Brunzell JD. Metabolic pathways of HDL subpopulations: physiological implications of in vitro observations. In: Carlson LA, ed. Disorders of HDL. Pp. 89-97. London: Smith, Gordon & Co, 1990.
50. Hennessy LK, Kunitake ST Kane JP. Apolipoprotein AI containing lipoproteins, with or without apolipoprotein AII, as progenitors of pre-β high density lipoprotein particles. Biochemistry 1993; 32: 5759-5765.
51. Duverger N, Rader D, Duchateau P, et al. Biochemical characterization of the three subclasses of lipoprotein A-I preparatively isolated from human plasma. Biochemistry 1993; 32: 12372-12379.
52. Lagrost L, Gambert P, Boquillon M, et al. Evidence for high density lipoproteins as the major apolipoprotein AIV-containing fraction in normal human serum. J Lipid Res 1989; 30: 1525-1534.
53. Bekaert ED, Alaupovic P, Knight-Gibson C, et al. Isolation and characterization of lipoprotein-AII (Lp-AII) particles of human plasma. Biochim Biophys Acta 1992; 1126: 105-113.
54. Assmann G, Herbert PN, Fredrickson S, et al. Isolation and characterization of an abnormal high density lipoprotein in Tangier disease. J Clin Invest 1977; 60: 242-252.
55. Deeb SS, Cheung MC, Peing R, et al. A mutation in the human apolipoprotein A-I gene. J Biol Chem 1991; 266: 13654-13660.
56. Cheung MC. Characterization and distribution of HDL subpopulations. In: Lippel K, ed. Proceedings of the workshop on lipoprotein heterogeneity. Pp. 341-349. NIH publ no. 87-2646. Bethesda, MD: National Institutes of Health, 1987.
57. Kunitake ST, La Sala KJ Kane JP. Apolipoprotein A-containing lipoproteins with pre-bêta electrophoresis mobility. J Lipid Res 1985; 26: 549-555.
58. Castro GR, Fielding CJ. Early incorporation of cell derived cholesterol into preβ-migrating high density lipoprotein. Biochemistry 1988; 27: 25-29.
59. Francone OL, Gurakar A Fielding C. Distribution and functions of lecithin-cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins AI and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 1989; 264: 7066-7072.
60. Fielding PE, Fielding CJ. A cholesteryl ester transfer complex in human plasma. Proc Natl Acad Sci USA 1980; 77: 3327-3330.
61. Burstein M, Scholnick HR Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-595.
62. Lopes-Virella MF, Stone P, Ellis S, et al. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-884.
63. Burstein M, Legman P. Lipoprotein precipitation. Basel: S Karger, 1982.
64. Bachorik PS, Albers JJ. Precipitation methods for quantitation of lipoproteins. Methods Enzymol 1986; 129: 78-100.
65. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with AI and AII and particles with AI but no AII. J Lipid Res 1982; 23: 747-753.
66. Koren E, Puchois P, Alaupovic P, et al. Quantification of two different types of apolipoprotein AI containing lipoprotein particles in plasma by enzyme-linked differential antibody immunosorbent assay. Clin Chem 1987; 33: 38-45.
67. Parra HJ, Mezdour H, Ghalim N, et al. Differential electroimmunoassay of human LpAI lipoprotein particles on ready-to-use plates. Clin Chem 1990; 36: 1431-1435.
68. Oram JF. Cholesterol trafficking in cells. Curr Opin Lipidol 1990; 1: 416-421.
69. Hokland B, Mendez AJ Oram JF. Cellular localization and characterization of proteins that bind high density lipoprotein. J Lipid Res 1992; 33: 1335-1342.
70. McKnight GL, Reasoner J, Gilbert T, et al. Cloning and expression of a cellular high density lipoprotein-binding protien that is up-regulated by cholesterol loading of cells. J Biol Chem 1992; 267: 12131-12141.
71. Slotte JP, Oram JF Bierman EL. Binding of high density lipoprotein to cell receptors promotes translocation of cholesterol from intracellular membrane to the cell surface. J Biol Chem 1987; 262: 12904-12907.
72. Aviram M, Bierman EL Oram JF. High density lipoprotein stimulates sterol translocation between intracellular and plasma membrane pools in human monocyte-derived macrophages. J Lipid Res 1989; 30: 65-76.
73. Mendez AJ, Oram JF Bierman EL. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem 1991; 266: 10104-10111.
74. Oram JF, Mendez AJ, Slotte JP, et al. High density apolipoproteins mediate removal of sterol from intracellular pools but not from plasma membranes of cholesterol-loaded fibroblasts. ArterioThromb 1991; 11: 403-414.
75. Theret N, Delbart C, Aguie G, et al. Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation. Biochem Biophys Res Commun 1990; 173: 1361-1368.
76. Schmitz G, Niemann R, Brennhausen B, et al. Regulation of high density lipoprotein receptors in cultured macrophages: role of acyl-CoA:cholesterol-acyltransferase. EMBO J 1985; 4: 2773-2779.
77. Schmitz G, Robenek H, Lohmann U, et al. Interaction of high density lipoproteins with cholesteryl ester-alden macrophages: biochemical and morphological characterization of cell surface receptor binding, endocytosis and resecretion of high density lipoproteins by macrophages. EMBO J 1985; 4: 613-622.
78. Phillips MC, McLean LR, Stoudt GW, et al. Mechanism of cholesterol efflux from cells. Atherosclerosis 1980; 36: 409-422.
79. Rothblat GH, Mahlberg FH, Johnson WJ, et al. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J Lipid Res 1992; 33: 1091-1097.
80. Johnson WJ, Mahlberg FH, Rothblat GH, et al. Cholesterol transport between cells and high density lipoproteins. Biochim Biophys Acta 1991; 1058: 273-298.
81. Phillips MC, Johnson WJ Rothblat GH. Mechanism and consequences of cellular cholesterol exchange and transfer. Biochem Biophys Acta 1987; 906: 223-276.
82. Glass C, Pittman RC, Weinberg DB, et al. Dissociation of tissue uptake of cholesterol esters from that of apo A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal and gonads. Proc Natl Acad Sci USA 1983; 80: 5435-5439.
83. Barr DP, Russ EM Eder HA. Protein-lipid relationship in human plasma. II. In atherosclerosis and related conditions. Am J Med 1951; 11: 480-493.
84. Gordon DJ, Rifkind BM. High density lipoprotein. The clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1316.
85. Salonen JT. Epidemiology of high density lipoproteins and atherosclerosis. In: Carlson LA, ed. Disorders of HDL. Pp 145-154. London: Smith-Gordon, 1990.
86. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
87. Blankenhorn DH, Alaupovic P, Wickman E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990; 81: 470-476.
88. Glomset JA. The plasma lecithin : cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155-167.
89. Parthasarathy S, Fong LG Steinberg D. Inhibitory effect of high density lipoprotein (HDL) on oxidative modification of low density lipoprotein (LDL). Circ Suppl Part II 1987; 76: IV-479.
90. Betteridge D. High density lipoprotein and coronary heart disease. Br Med J 1989; 298: 974-975.
91. Lewis B. The lipoproteins: predictors, protectors, and pathogens. Br Med J 1983; 287: 1161-1164.
92. Khoo JC, Miller E, McLoughlin P, et al. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res 1990; 31: 645-652.
93. Knorr M. Rapid activation of human platelets by low concentrations of low density lipoprotein via phosphatidylinositol cycle. Eur J Biochem 1988; 172: 753-759.
94. Kibe A, Holzbach RT, La Russo NF, et al. Inhibition of cholesterol crystal formation by apolipoprotein in super-saturated model bile. Science 1984; 255: 514-516.
95. Puchois P, Luyeye C Alaupovic P. Comparison of four procedures for separating apolipoprotein A- and apolipoprotein B-containing lipoproteins in plasma. Clin Chem 1987; 33: 1597-1602.
96. Miller NE. Association of high density subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589-597.
97. Silveman DI, Ginsburg GS Pasternak RC. High density lipoproein subfractions. Am J Med 1993; 94: 636-645.
98. Kempen HJ, Van Gent CM, Buytenhek R, et al. Association of cholesterol concentrations in low density lipoprotein, high density lipoprotein, and high density lipoprotein subfractions, and of apolipoprotein A-I and A-II, with coronary stenosis and left ventricular function. J Lab Clin Med 1987; 109: 19-26.
99. Miller NE, Hammett F Saltissi S. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 1981; 282: 1741-1744.
100. Gofman JW, Young W Tandy R. Ischemic heart disease, atherosclerosis and longevity. Circulation 1966; 34: 679-697.
101. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381.
102. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-882.
103. Kottke BA, Zinsmeister AR, Holmes DR, et al. Apolipoproteins and coronary heart disease. Mayo Clin Proc 1986; 61: 313-320.
104. Coste-Burel V, Mainard F, Chivot L, et al. Study of lipoprotein particles LpA-I and LpA-I:A-II in patients before coronary bypass surgery. Clin Chem 1990; 36: 1889-1891.
105. Cheung MC, Brown MG, Wolf A, et al. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991; 32: 383-394.
106. Genest JJ, Bard JM, Fruchart JC, et al. Plasma apoliporpoteins A-I, A-II, B, E, C-III-containing particles in men with premature coronary artery disease. Atherosclerosis 1991; 90: 149-157.
107. Parra HJ, Arveiler D, Evans AE, et al. A case control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. J Lipid Res 1992; 12: 701-707.
108. Montali A, Vega GL Grundy SM. Concentrations of apoliporpotein A-I-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb 1994; 14: 511-517.
109. Amouyel P, Isorez D, Bard JM, et al. Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler Thromb 1993; 13: 1640-1644.
110. Johnson WJ, Kilsdonk EPC, Van Tol A, et al. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LpA-I and LpA-I:A-II. J Lipid Res 1991; 32: 1993-2000.
111. Johansson J, Mölgaard J, Olsson AG, et al. Effects of probucol treatment on HDL particle size subclass concentrations as assessed by gradient gel electrophoresis. In: Carlson LA, ed. Disorders of HDL. London: Smith-Gordon, 1990.
112. Johansson J, Carlson LA. High density lipoprotein particle size subclass alterations by treatment with nicotinic acid. In: Carlson LA, ed. Disorders of HDL. London: Smith-Gordon, 1990.
113. Taskinen MR, Nikkilä EA, Välimäki M, et al. Alcohol-induced changes in serum lipoproteins and their metabolism. Am Heart J 1987; 113: 458-464.
114. Puchois P, Ghalim N, Zylberberg G, et al. Effect of alcohol intake on human apolipoprotein A-I containing lipoprotein subfractions. Arch Intern Med 1990; 150: 1638-1641.
115. Välimäki M, Kahri J, Laitinen K, et al. High density lipoprotein subfractions, apolipoprotein A-I containing lipoproteins, lipoprotein (a), and cholesterol ester transfer protein activity in alcoholic women before and after ethanol withdrawal. Eur J Clin Invest 1993: 23: 406-417.
116. Hartung GH, Foreyt JP, Reeves RS, et al. Effect of alcohol dose on plasma lipoprotein subfractions and lipolytic enzyme activity in active and inactive men. Metabolism 1990; 39: 81-86.
117. Dunn FL. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 1990; 6: 47-61.
118. Nikkilä EA, Hormila P. Serum lipids and apolipoproteins in insulin-treated diabetes. Demonstration of increased high-density lipoprotein concentration. Diabetes 1978; 27: 1078-1086.
119. Taskinen MR. Hyperlipidemia in diabetes. Baillieres Clin Endocrinol Metab 1990; 4: 743-775.
120. Kahri J, Groop PH, Viberti G, et al. Regulation of apolipoprotein A-I-containing lipoproteins in IDDM. Diabetes 1993; 42: 1281-1288.
121. Mattock MB, Salter AM, Fuller JH, et al. High density lipoprotein subfractions in insulin-dependent diabetic and normal subjects. Atherosclerosis 1982; 45: 67-79.
122. Steinbrecher UP, Witztum JL. Glycosylation of low density lipoprotein to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-134.
123. Duell BP, Oram JF Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991; 40: 377-384.
124. Fievet C, Theret N, Shojaee N, et al. Apolipoprotein A-I containing particles and reverse cholesterol transport in type I diabetes. Diabetes 1992; 41: 81-85.
125. Cachera C, Kandoussi A, Equagoo K, et al. Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis. Am J Nephrol 1990; 10: 171-172.
126. Luc G, Bard JM, Lussier-Cacan S, et al. High density lipoprotein particles in octogenarians. Metabolism 1991; 40: 1238-1243.
127. Brewer HB, Rader D, Fojo S, et al. Frontiers in the analysis of HDL structure, function and metabolism. In: Carlson LA, ed. Disorders of HDL. Pp. 51-58. London: Smith-Gordon, 1990.
128. Blum CB, Levy RI, Eisenberg S, et al. High density lipoprotein metabolism in man. J Clin Invest 1977; 60: 795-807.
129. Shepherd J, Packer CJ, Patsch JR, et al Effects of dietary saturated and polyunsaturated fat on the properties of high density lipoproteins and the metabolism of apoprotein AI. J Clin Invest 1978; 61: 1582-1592.
130. Ehnholm C, Huttunen JK, Pietinen P, et al. Effect of a diet low in unsaturated fatty acids on plasma lipids, lipoproteins and HDL subfractions. Arteriosclerosis 1984; 4: 265-269.
131. Mensik RP, Katan MB. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low density and high density lipoprotein cholesterol on healthly women and men. N Engl J Med 1989; 321: 436-441.
132. 1-3. Am J Clin Nutr 1991; 53: 655-659.
133. Mistry P, Miller NE, Laker M, et al. Individual variations in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. J Clin Invest 1981; 67: 493-502.
134. Baumstark MW, Frey I, Berg A., et al. Influence of n-3 fatty acids from fish oils on concentration of high and low density lipoprotein subfractions and their lipid and apolipoprotein composition. Clin Biochem 1992; 25: 338-340.
135. Fragoso YD, Skinner ER. The effect of gammalinolenic acid on the subfractions of plasma high density lipoprotein of the rabbit. Biochem Pharmaol 1992; 44: 1085-1090.
136. Rye KA, Garrety KH Barter PJ. Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J Lipid Res 1992; 33: 215-224.
137. Sopko G, Leon AS, Jacobs DR, et al. The effects of exercise and weight loss on plasma lipids in young obese men. Metabolism 1985; 34: 227-236.
138. Eckel RH, Yost TJ. HDL subfractions and adipose tissue metabolism in the reduced-obese state. Am J Physiol 1989; 256: E740-E746.
139. Williams PT, Krauss RM, Vranizan KM, et al. Effects of weight-loss by exercise and by diet on apolipoproteins AI and AII and the particle size distribution of high density lipoproteins in men. Metabolism 1992; 41: 441-449.
140. Levy RI, Brensike JF, Epstein SF, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 325-337.
141. Lipid Research Clinics Program. The lipid research clinics primary prevention trial results. I. Reduction in incidence of coronary disease. JAMA 1984; 251: 351-364.
142. Shepherd J, Packard CJ, Morgan HG, et al. The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 1979; 33: 33-44.
143. Witztum JL, Schonfeld G, Weidman SW, et al. Bile sequestrant therapy alters the composition of low density and high density lipoproteins. Metabolism 1979; 28: 221-229.
144. Cheung MC, Albers JJ, Wahl PW, et al. High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. Atherosclerosis 1980; 35: 215-228.
145. Bard JM, Parra HJ, Douste-Blazy P, et al. Effect of pravastatin, an HMG-CoA reductase inhibitor, and cholestyramine, a bile-acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1990; 39: 269-273.
146. Shepherd J, Packard CJ, Patsch JR, et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63: 858-867.
147. Johansson J, Carlson LA. The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidemic subjects. Atherosclerosis 1990; 83: 207-216.
148. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of modified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 650-652.
149. Hunninghake DB, Bell C Olson L. Effect of probucol on plasma lipids and lipoprotein in type IIb hyperlipoproteinemia. Atherosclerosis 1980; 37: 469-474.
150. Mellies MJ, Gartside PS, Glatfelter L, et al. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol and apolipoprotein AI and AII in adults with primary familial hypercholesterolemia. Metabolism 1980; 29: 956-964.
151. Glueck CJ. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Ann Intern Med 1982; 96: 475-482.
152. Nestel PJ, Billington T. Effect of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 1981; 38: 203-209.
153. Atmeh RF, Steward JM, Boag DE, et al. The hypolipidemic action of probucol: a study of its effect on high and low density lipoproteins. J Lipid Res 1983; 24: 585-595.
154. Lock DR, Kuisk I, Gonen B, et al. Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover. Atherosclerosis 1983; 47: 271-278.
155. Jones DB, Simpson HC, Slaughter P, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolemia. Atherosclerosis 1984; 53: 1-7.
156. Durrington PN, Miller JP. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55: 187-194.
157. Franceschini G, Sirtori M, Vaccarino V, et al. Mechanisms of HDL reduction after probucol changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989; 9: 462-469.
158. Sirtori CR, Franceschini G. Effects of fibrates on serum lipids and atheroslcerosis. Pharmacol Ther 1988; 37: 167-191.
159. Saku K, Gartside PS, Hynd BA, et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-1712.
160. Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55: 161-169.
161. Fruchart JC, Parra HJ Bard JM. Comparative effects of pravastatin, simvastatin, fenofibrate and cholestyramine on plasma apolipoprotein AI-containing plasma lipoprotein particles. J Drug Dev 1990; 3: 103-106.
162. Mol MJTM, Erkelens DW, Gevers Leuven IA, et al. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet 1986; 2: 936.
163. Mölgaard J, Von Schenk H Olsson AG. Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolemia. Eur Heart J 1988; 9: 541.
164. Todd PA, Goa KL. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990; 40: 583.
165. Franceschini G, Sinon M, Vaccarino V, et al. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med 1989; 114: 250-259.
166. Johansson J, Mölgaard J Olsson AG. Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolemia. Atherosclerosis 1991; 91: 175-184.
167. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-49.
168. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992; 41: 498-503.